Akcea Therapeutics (AKCA) Tops Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Akcea Reports Financial Results and Highlights for Third Quarter 2019
November 5, 2019 4:06 PM ESTReported Third Quarter 2019 Global Net Product Revenues of $12 Million
WAYLIVRA® (volanesorsen) launched in the E.U.
Entered into a worldwide licensing agreement with Pfizer, Inc. for AKCEA-ANGPTL3-LRx
Conference Call Webcast Tuesday, November 5, 4:30 p.m. ET... More
